| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000013641 |
| Receipt No. | R000015921 |
| Scientific Title | Exploratory clinical study on effects to the blood flow and safety of transcutaneous application of carbon dioxide for fractured limbs |
| Date of disclosure of the study information | 2014/07/01 |
| Last modified on | 2019/12/10 (Ver. 13) |
| Basic information | ||
| Public title | Exploratory clinical study on effects to the blood flow and safety of transcutaneous application of carbon dioxide for fractured limbs | |
| Acronym | Investigation of effects of transcutaneous application of carbon dioxide to fractured limbs | |
| Scientific Title | Exploratory clinical study on effects to the blood flow and safety of transcutaneous application of carbon dioxide for fractured limbs | |
| Scientific Title:Acronym | Investigation of effects of transcutaneous application of carbon dioxide to fractured limbs | |
| Region |
|
|
| Condition | ||
| Condition | fracture | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To assess accelerating effects to the blood flow and safety of transcutaneous application of carbon dioxide for fractured limbs |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Validation of accelerating effects to the blood flow of transcutaneous application of carbon dioxide for fractured limbs |
| Key secondary outcomes | Validation of safety of transcutaneous application of carbon dioxide for fractured limbs |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |||
| No. of arms | 1 | ||
| Purpose of intervention | Treatment | ||
| Type of intervention |
|
||
| Interventions/Control_1 | Transcutaneous application of carbon dioxide to fractured limbs | ||
| Interventions/Control_2 | |||
| Interventions/Control_3 | |||
| Interventions/Control_4 | |||
| Interventions/Control_5 | |||
| Interventions/Control_6 | |||
| Interventions/Control_7 | |||
| Interventions/Control_8 | |||
| Interventions/Control_9 | |||
| Interventions/Control_10 | |||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients with fracture of lower extremities
Both acute phase and chronic phase of fracture Nonunion and bone defect Age over 15 Written informed consent Closed fracture and open fracture Conservative treatment and surgical treatment Any methods of surgical treatment |
|||
| Key exclusion criteria | Pathological fracture
Peripheral artery disease or ischemia in the fractured limb Skin disease in the fractured limb Infection in the fractured limb Inadequate condition both general and local No written informed consent Patients who are judged as contraindication with any reasons by the doctors in charge |
|||
| Target sample size | 20 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Kobe University Graduate School of Medicine | ||||||
| Division name | Orthopaedic Surgery | ||||||
| Zip code | 650-0017 | ||||||
| Address | 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Japan | ||||||
| TEL | 078-382-5985 | ||||||
| tniikura@med.kobe-u.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Kobe University Graduate School of Medicine | ||||||
| Division name | Orthopaedic Surgery | ||||||
| Zip code | 650-0017 | ||||||
| Address | 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Japan | ||||||
| TEL | 078-382-5985 | ||||||
| Homepage URL | |||||||
| tniikura@med.kobe-u.ac.jp | |||||||
| Sponsor | |
| Institute | Kobe University Graduate School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kobe University Graduate School of Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Clinical & Translational Research Center, Kobe University Hospital |
| Address | 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Japan |
| Tel | 078-382-6669 |
| chiken@med.kobe-u.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 神戸大学医学部附属病院(兵庫県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | Not applicable |
| Publication of results | Published |
| Result | |||||||
| URL related to results and publications | Not applicable | ||||||
| Number of participants that the trial has enrolled | 20 | ||||||
| Results | Nineteen patients were subjected to complete analysis. No adverse events were observed. Arterial and expired gas analyses revealed no adverse systemic effects including hypercapnia. The mean ratio of blood flow 20 min after CO2 therapy compared with the pre-treatment level increased by approximately 2-fold in a time-dependent manner. |
||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results |
|
||||||
| Baseline Characteristics | Twenty patients were enrolled to the trial in accordance with the study design. One of the patients dropped out. Therefore, all analyses were conducted using the data obtained from the remaining 19 patients. Of the 19 patients for whom complete data analyses were performed, 13 were men and six were women, with a mean age of 48.7 years and mean body mass index of 25.6. |
||||||
| Participant flow | Patients with fractures of the femur and tibia were prospectively enrolled into this study with ethical approval and informed consent. The CO2 absorption-enhancing hydrogel was applied to the fractured lower limbs of patients, and then 100% CO2 was administered daily into a sealed space for 20 min over 4 weeks postoperatively. |
||||||
| Adverse events | None |
||||||
| Outcome measures | Safety was assessed based on vital signs, blood parameters, adverse events, and arterial and expired gas analyses. As the efficacy outcome, blood flow at the level of the fracture site and at a site 5 cm from the fracture in the affected limb was measured using a laser Doppler blood flow meter. |
||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | Published in the BMC Musculoskeletal Disorders on November 25, 2019. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015921 |